Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Human respiratory syncytial virus (hRSV) is the leading cause of infant hospitalization related to respiratory disease. Infection with hRSV produces abundant infiltration of immune cells into the airways, which combined with an exacerbated pro-inflammatory immune response can lead to significant damage to the lungs. Human RSV re-infection is extremely frequent, suggesting that this virus may have evolved molecular mechanisms that interfere with host adaptive immunity. Infection with hRSV can be reduced by administering a humanized neutralizing antibody against the virus fusion protein in high-risk infants. Although neutralizing antibodies against hRSV effectively block the infection of airway epithelial cells, here we show that both, bone marrow-derived dendritic cells (DCs) and lung DCs undergo infection with IgG-coated virus (hRSV-IC), albeit abortive. Yet, this is enough to negatively modulate DC function. We observed that such a process is mediated by Fcγ receptors (FcγRs) expressed on the surface of DCs. Remarkably, we also observed that in the absence of hRSV-specific antibodies FcγRIII knockout mice displayed significantly less cellular infiltration in the lungs after hRSV infection, compared with wild-type mice, suggesting a potentially harmful, IgG-independent role for this receptor in hRSV disease. Our findings support the notion that FcγRs can contribute significantly to the modulation of DC function by hRSV and hRSV-IC. Further, we provide evidence for an involvement of FcγRIII in the development of hRSV pathogenesis.

Original publication

DOI

10.1111/imm.12541

Type

Journal article

Journal

Immunology

Publication Date

01/2016

Volume

147

Pages

55 - 72

Keywords

Fcγ receptors, dendritic cells, human respiratory syncytial virus, immune complexes, neutralizing antibodies, palivizumab, Adaptive Immunity, Animals, Antibodies, Neutralizing, Antibodies, Viral, Antiviral Agents, Cells, Cultured, Coculture Techniques, Cytokines, Dendritic Cells, Disease Models, Animal, Immunoglobulin G, Lung, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Knockout, Palivizumab, Receptors, IgG, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Signal Transduction, T-Lymphocytes, Viral Load, Virus Replication